Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Athinoula A Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, MA.
Ann Surg. 2023 Apr 1;277(4):e893-e899. doi: 10.1097/SLA.0000000000005418. Epub 2022 Feb 17.
To compare positron emission tomography (PET)/magnetic resonance imaging (MRI) to the standard of care imaging (SCI) for the diagnosis of peritoneal carcinomatosis (PC) in primary abdominopelvic malignancies.
Identifying PC impacts prognosis and management of multiple cancer types.
Adult subjects were prospectively and consecutively enrolled from April 2019 to January 2021. Inclusion criteria were: 1) acquisition of whole-body contrast-enhanced (CE) 18F-fluorodeoxyglucose PET/MRI, 2) pathologically confirmed primary abdominopelvic malignancies. Exclusion criteria were: 1) greater than 4 weeks interval between SCI and PET/MRI, 2) unavailable follow-up. SCI consisted of whole-body CE PET/computed tomography (CT) with diagnostic quality CT, and/or CE-CT of the abdomen and pelvis, and/or CE-MRI of the abdomen±pelvis. If available, pathology or surgical findings served as the reference standard, otherwise, imaging followup was used. When SCI and PET/MRI results disagreed, medical records were checked for management changes. Follow-up data were collected until August 2021.
One hundred sixty-four subjects were included, 85 (52%) were female, and the median age was 60 years (interquartile range 50-69). At a subject level, PET/MRI had higher sensitivity (0.97, 95% CI 0.86-1.00) than SCI (0.54, 95% CI 0.37-0.71), P < 0.001, without a difference in specificity, of 0.95 (95% CI 0.90-0.98) for PET/MRI and 0.98 (95% CI 0.93-1.00) for SCI, P ¼ 0.250. PET/MRI and SCI results disagreed in 19 cases. In 5/19 (26%) of the discordant cases, PET/MRI findings consistent with PC missed on SCI led to management changes.
PET/MRI improves detection of PC compared with SCI which frequently changes management.
比较正电子发射断层扫描(PET)/磁共振成像(MRI)与标准影像学检查(SCI)在原发性腹盆腔恶性肿瘤腹膜癌(PC)诊断中的应用。
确定 PC 会影响多种癌症类型的预后和管理。
2019 年 4 月至 2021 年 1 月,前瞻性连续纳入成年受试者。纳入标准为:1)全身对比增强(CE)18F-氟脱氧葡萄糖 PET/MRI 检查;2)经病理证实的原发性腹盆腔恶性肿瘤。排除标准为:1)SCI 与 PET/MRI 检查之间的间隔大于 4 周;2)无随访。SCI 包括全身 CE PET/计算机断层扫描(CT),同时行诊断质量 CT 检查,以及(或)腹部和骨盆 CE-CT 检查,和(或)腹部+骨盆 CE-MRI 检查。如果可行,以病理或手术结果作为参考标准,否则采用影像学随访。当 SCI 和 PET/MRI 结果不一致时,检查病历以确定是否进行了治疗方案的调整。收集随访数据至 2021 年 8 月。
共纳入 164 名受试者,85 名(52%)为女性,中位年龄为 60 岁(四分位间距 50-69 岁)。以个体为单位,PET/MRI 的敏感性(0.97,95%CI 0.86-1.00)高于 SCI(0.54,95%CI 0.37-0.71),P<0.001,特异性分别为 0.95(95%CI 0.90-0.98)和 0.98(95%CI 0.93-1.00),P=0.250。PET/MRI 和 SCI 结果不一致的有 19 例。在 19 例不一致的病例中,有 5 例(26%)PET/MRI 发现的 SCI 漏诊的 PC 导致了治疗方案的改变。
与 SCI 相比,PET/MRI 可提高 PC 的检出率,而 SCI 常改变治疗方案。